Metastasis-related genes in prostate cancer: The role of caveolin-1

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 439-442

  Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Androgen resistance; Caveolin 1; Metastasis; Prostate cancer

Indexed keywords

ANDROGEN; CAVEOLIN; MESSENGER RNA;

ANIMAL CELL; CANCER GROWTH; CANCER SCREENING; GENE EXPRESSION; GENE REPRESSION; GENE SEQUENCE; HORMONE RESISTANCE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; UNITED STATES;

EID: 0032774407     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006110326366     Document Type: Review

References (18)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 47: 5-27, 1997
2. Lu-Yao GL, McLarren D, Wasson J, Wennberg JE: An assessment of radical prostatectomy time trends, geographic variation and outcomes. The prostate patient outcomes research Team. JAMA 269: 2633-2636, 1993
3. Surveillance, Epidemiology, and End Results (SEER) Program. Age-adjusted U.S. cancer death rates. J Natl Inst 89:12, 1997
4. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154:1818-1824, 1995
5. Zeitman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ: Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43: 828-833,1994
6. Sakr WA, Macoska JA, Benson PD, et al.: Allelic loss in locally metastaric, multi-sampled prostate cancer. J Urol 54:3273-3279, 1994
7. Qian J, Bostwick DG, Takashi S, et al.: Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55: 5408-5414, 1995
8. Thompson TC, Park SH, Timme RL, et al.: Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 10: 869-879, 1995
9. Kinzler K, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996
10. Thompson TC, Timme TL, Schgal I: Oncogenes, growth factors, and hormones in prostate cancer. In Hormones and Growth Factors in Development and Neoplasia. Dickson RB, Salomon DS, (eds), John Wiley and Sons, Inc, NewYork, 1998
11. Thompson TC, Timme TL, Sehgal I: The role of p53 in prostate cancer progression. In Accomplishments in Cancer Research, 1996. Fortner JG, Sharp PA, (eds), Lippincott-Raven, Philadelphia: 280-289, 1996
12. Hall SJ, Thompson TC: Spontaneous metastatic activities but not experimental metastatic activities differentiate primary tumor-derived versus metastasis-derived mouse prostate cancer cell lines. Clin Exp Metastasis 15: 484-493, 1997
13. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Scardino PT, Thompson TC: Elevated expression of caveolin is associated with progression in prostate and breast cancer. Clin Cancer Res 4: 1873-1880, 1998
14. Harder T, Simons K: Caveolac, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol 9: 534-542, 1997
15. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC: Suppression of caveolin expression induces androgen sensitivity in metastatic androgen insensitive mouse prostate cancer cells. Nature Med 4: 1062-1064, 1998
16. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP: Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. J Biol Chem 272: 16974-16981, 1997
17. Lee SW, Reimer CL, Oh P, Campbell DB, Schmitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16: 1391-1397, 1998
18. Lavie Y, Fiucci G, Lisrovitch M: Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 273: 32380-32383, 1998